Two Ph3 data results coming in January that will probably be positive based on the first trial's results. Look for this to go to FDA by mid year for approval. LOW FLOAT, plenty of institution and insider ownership...I'm loving this stock all the way to 9-10 a share by end of next year. I look for 6 by March.
It had quite a run up from 3.31 (secondary offering price) to 4 'ish. Then the volume fell off the cliff last two weeks...since it has such a low float, not much in volume can be had. But man if someone steps up and starts buying it will rise quickly. This thing is pretty much off the radar in the micrcap world and much better quality than most I trade.